5 notable AI advances presented at RSNA 2020

There was nothing virtual about the interest in AI at the virtual annual meeting of the Radiological Society of North America Nov. 29 to Dec. 5.

Despite the lack of actual foot traffic, more than 105 exhibitors presented AI-specific wares in the virtual AI showcase. That was down from 2019’s pre-COVID 150 or so but still easily beat 2018’s head count, around 75.

Meanwhile the 2020 show’s scientific sessions and press conferences broke several noteworthy developments. Here are links to coverage of five (in no special order):

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.